Oral mucositis is a gastrointestinal inflammation that can cause several problems in the human body. It can affect the general nutritional intake of a person. Oral mucositis is a common health issue arising from cancer treatment and other factors. It causes several problems that include pain, nutritional problems as a result of inability to eat, and an increased risk of infection due to open sores in the mucosa.
The U.S. Severe oral mucositis Market is estimated to be valued at US$ 78.5 Mn in 2021 and is expected to exhibit a CAGR of 19.2% during the forecast period (2021-2028).
Figure 1.U.S. Severe Oral Mucositis Market Share (%) in Terms of Value, By Drug Type, 2021
Increasing prevalence of head and neck cancer in the U.S. is expected to drive the market growth during the forecast period.
The increasing prevalence of head and neck cancer is a primary driving factor for the growth of the U.S. severe oral mucositis market over the forecast period. According to the American Society of Clinical Oncology (ASCO)’s 2021 report, approximately 4% of individuals suffered from head and neck cancer in the U.S. and an estimate of 66,630 people (48,740 men and 17,890 women) were expected to develop head and neck cancer.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 78.5 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2021 to 2028 CAGR: | 19.2% | 2028 Value Projection: | US$ 267.7 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2 .U.S. Severe Oral Mucositis Market Share (%), by Cause, 2021
Key players are focusing on inorganic strategies and fund raising, which is expected to drive the market growth during the forecast period.
The key players in the U.S. are focusing on fund raising activities for boosting research and development for the treatment of severe oral mucositis caused due to radiation and chemotherapy in the cancer patients. For instance, in September 2018, Galera Therapeutics, Inc., a company developing novel mechanism-based therapies, announced that the company secured US$ 150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, and Tekla Capital Management LLC. The existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures, and Sofinnova Ventures also participated.
U.S. Severe Oral Mucositis Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products, and affected the growth of several oral mucositis medication businesses of various companies across the regions such as North America (U.S.). COVID-19 pandemic led to an unprecedented lockdown in several countries such as U.S. This lockdown resulted in closure of industrial establishments except manufacturing of essential commodities and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by various governments in the past few months, while countries such as Brazil, France, Russia, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Due to severe shortage of medical resources at the front line, only patients diagnosed with serious conditions are being hospitalized. Unfortunately, the pathogenic mechanism of the virus has not been identified completely, even though, vaccines and drugs are being manufactured by various companies for prevent and treat COVID-19. The COVID-19 pandemic has impacted the global economy and in turn, the U.S. severe oral mucositis market. Quarantine, traveling constraints, and social distancing measures are likely to cause a steep decline in business and consumer spending until the end of the first quarter of 2021.
U.S. Severe Oral Mucositis Market: Restraint
The major factors that hinder growth of the U.S. severe oral mucositis market include high incremental cost associated with severe oral mucositis in cancer patients. For instance, according to the report published by Oxford University Press in 2019, patients undergoing chemotherapy and radiation therapy for the treatment of head and neck cancers have to pay incremental cost for the treatment of complications associated with the treatments such as severe oral mucositis. According to the same source, patients have to pay extra US$ 5,000– 30,000 for the treatment of oral mucositis that was induced due to radiation therapy while patients had to pay US$ 3,700 per cycle for oral mucositis induced due to chemotherapy in the U.S. This treatment cost included hospitalization fees, medication cost (medications included are kepivance (Palifermin), analgesic drugs, and systemic infusions in severe cases, among others), and others.
Key Players
Major players operating in the U.S. severe oral mucositis market are Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group
Oral mucositis refers to tissue swelling in the mouth. Radiation therapy or chemotherapy may cause mucositis. Oral mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer who are treated with chemotherapy, and/or with radiation therapy. Lesions of oral mucositis are often very painful and compromise nutrition and oral hygiene as well as increase the risk for local and systemic infection. Oral mucositis is a significant and dose-limiting toxicity of cancer therapy with important clinical and economic implications. Oral mucositis from chemotherapy or radiation treatment can last from 7 to 98 days.
Market Dynamics
The key players in the market are focused on growth strategies such as FDA approvals, which are expected to drive the growth of the market over forecast period. For instance, in November 2016, Oragenics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AG013, the company’s lead therapeutic candidate for the treatment of oral mucositis. Furthermore, in April 2018, Enzychem Lifesciences announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EC-18 for the treatment of chemo-radiation induced oral mucositis. Moreover, key companies focusing on research and development of severe oral mucositis are expected to drive the growth of the market over forecast period. For instance, in December 2019, Oragenics, Inc., announced the completion of enrolment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, which is an easy-to-use oral rinsing system designed to prevent and treat oral mucositis.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients